MedImmune, Inc. has been awarded a contract from the U.S. Department of Health and Human Services (HHS) to modify its U.S. vaccine manufacturing facilities to produce pandemic influenza vaccines using its live, attenuated, needle-free technology. The total value of the fully funded base contract is approximately $55.1 million. MedImmune will contribute approximately $14 million to the retrofitting of its U.S. vaccine manufacturing facilities. MedImmune’s marketed flu vaccine, FluMist,...